



CCS/CHRS Position Statement on the Management of Ventricular Tachycardia and Fibrillation in Patients with Structural Heart Disease

Panel Member's Relationships with Industry (RWI)

The CCS is committed to preserving the scientific integrity of its Guidelines and Position Statements through transparency and management of relationships with industry (RWI). Panel members must disclose all relationships with industry regardless of relevance to the statement topic (see below). When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit www.ccs.ca.

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.			
	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Primary Panel				
Marc W. Deyell	Abbott Canada, BMS Pfizer, Boehringer Ingelheim, Johnson & Johnson, Servier	Abbott Canada, BMS Pfizer, Johnson & Johnson	None	
John L. Sapp	Medtronic, St. Jude Medical	St. Jude Medical	Johnson & Johnson, Abbott	Partial funding support for a clinical trial of management options for VT
Amir Abdel-Wahab	Abbott Canada, Medtronic	None	None	Honoraria for participation in educational activities related to ICDs
Paul Angaran	BMS Pfizer, Servier	Bayer, BMS Pfizer, Boehringer Ingelheim, Medtronic, St. Jude Medical	None	None
Vidal Essebag	Abbott Canada, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Johnson & Johnson, Medtronic, Novartis, Pfizer, Servier	Abbott Canada, Bayer, BMS Pfizer, Boehringer Ingelheim, Boston Scientific, Johnson & Johnson, Medtronic	None	Some of the companies listed sell devices or ablation catheters used to treat VT
Benedict Glover	Abbott, Bayer, Servier	None	None	None
Lorne J. Gula	Bayer	None	None	None
Clarence Khoo	None	None	None	None
Christopher Lane	Bayer, Biosense Webster, BMS Pfizer	Bayer, Medtronic	None	None
Isabelle Nault	Bayer, BMS Pfizer, Novartis, Servier	Abbott Canada, Bayer, Boston Scientific, Medtronic, St. Jude Medical	Johnson & Johnson	None
Pablo B. Nery	None	None	None	None
Lena Rivard	Bayer, Boston Scientific, Johnson & Johnson, St. Jude Medical	Bayer, St. Jude Medical, icentia	None	None
Michael P. Slawnych	Novartis	None	None	None
Heather L. Tulloch	None	None	None	None

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.			
	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Secondary Panel				
P. Timothy Pollak	None	None	None	
Vikas Kuriachan	Abbott Canada, Bayer, Boston Scientific, Johnson & Johnson, Medtronic, Servier	Abbott Canada, Boston Scientific, Servier, St. Jude Medical	None	Abbott / St. Jude medical - Local co-i on leadless pacemaker study. BSC - Local co-i on SICD vs Transvenous ICD study (ATLAS). Also local co-i on Watchman studies (ASAP-TOO and Stop HARM) Servier - Local co-i on afib ablation study with uninterrupted edoxaban.
Eugene Crystal	None	Abbott Canada, St. Jude Medical, Stereotaxis, Biotronik	None	None
Peter Leong-Sit	Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Johnson & Johnson, Medtronic, Pfizer, St. Jude Medical	Johnson & Johnson, St. Jude Medical	None	Consulting fees and speaker honoraria from industry related to cardiac device (ICD) implantation, cardiac catheter ablation, and systemic anticoagulation. Clinical trials on cardiac ablation for VT.
Paul Dorian	Bayer, BMS Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Servier	Bayer, BMS Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer	None	None
Jacqueline Joza	Boston Scientific, Servier	Bayer, BMS Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer	None	None